UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,922	01/30/2006	Philip John Hogg	05-363	1798
	7590 04/09/200 BOEHNEN HULBER	EXAMINER		
300 S. WACKE		STONE, CHRISTOPHER R		
32ND FLOOR CHICAGO, IL	60606		ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			04/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/534,922	HOGG, PHILIP JOHN		
Examiner	Art Unit		
CHRISTOPHER R. STONE	1614		

	CHRISTOPHER R. STONE	1014	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>23 March 2009</u> FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR	ALLOWANCE.	
<ol> <li>The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 Coperiods:</li> </ol>	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth intermental ater than SIX MONTHS from the mailing	date of the final rejection	n.
Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	7).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply original controls.	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be f	filed within two months	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
<u>AMENDMENTS</u>			
<ol> <li>The proposed amendment(s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection, to a limit in the proposed amendment (s) filed after a final rejection (s).</li> </ol>			cause
(b) They raise the issue of new matter (see NOTE below	•		
(c) ☑ They are not deemed to place the application in beti appeal; and/or			ne issues for
(d)⊠ They present additional claims without canceling a c		cted claims.	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1)			
4. $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	21. See attached Notice of Non-Co	mpliant Amendment (	PTOL-324).
<ol><li>Applicant's reply has overcome the following rejection(s):</li></ol>			
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>			_
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed:		l be entered and an e	xplanation of
Claim(s) objected to:			
Claim(s) rejected: <u>1-5,9-19,23,27 and 28</u> . Claim(s) withdrawn from consideration: <u>6-8,20-22 and 24-</u>	<u>26</u> .		
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail	s to provide a
<ol> <li>The affidavit or other evidence is entered. An explanation <u>REQUEST FOR RECONSIDERATION/OTHER</u></li> </ol>	n of the status of the claims after er	ntry is below or attach	ed.
<ol> <li>The request for reconsideration has been considered but <u>See Continuation Sheet.</u></li> </ol>	does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (	PTO/SB/08) Paper No(s)		
13.  Other:			
	/Patricia A. Duffy/ Primary Examiner, Art U	nit 1645	
	,, ,, ,		

Continuation of 3. NOTE: The amendment adds another active step to the instantly claimed method, i.e. contacting more than one cell, and therefore would require further search an consideration of the new limitations.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's argument are based on a lack of reasonable expectation of success in isolating a compound that selectively induces the mitochodrial permeability transition in proliferating cells as compared to non-proliferating cells; However the instant claims do not require the isolation of such a compound. In other words, the instantly claimed screening method (contacting a cell, determining whether the compound binds adenine nucleotide translocator and determining whether the compound selectively induces the mitochondrial permeability transition in proliferating cells as compared to non-proliferating cells) can be practiced with any compound, that is the determination steps do not require that the compound has the desired activity.